US Pharma MarketingArgenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis
Argenx said Monday that Vyvgart Hytrulo passed a late-stage test in a family of rare autoimmune diseases, even though the drug missed the mark in a key patient subgroup. The subcutaneous drug
Argenx said Monday that Vyvgart Hytrulo passed a late-stage test in a family of rare autoimmune diseases, even though the drug missed the mark in a key patient subgroup.
The subcutaneous drug
Source: Endpoints News